On Invalid Date, Seres Therapeutics (NASDAQ: MCRB) reported Q4 2023 earnings per share (EPS) of -$0.32, up 40.74% year over year. Total Seres Therapeutics earnings for the quarter were -$41.25 million. In the same quarter last year, Seres Therapeutics's earnings per share (EPS) was -$0.54.
As of Q2 2024, Seres Therapeutics's earnings has grown year over year. Seres Therapeutics's earnings in the past year totalled -$113.72 million.
What is MCRB's earnings date?
Seres Therapeutics's earnings date is Invalid Date. Add MCRB to your watchlist to be reminded of MCRB's next earnings announcement.
What was MCRB's revenue last quarter?
On Invalid Date, Seres Therapeutics (NASDAQ: MCRB) reported Q4 2023 revenue of $64.00 thousand up 93.44% year over year. In the same quarter last year, Seres Therapeutics's revenue was $975.00 thousand.
What was MCRB's revenue growth in the past year?
As of Q2 2024, Seres Therapeutics's revenue has grown 1,672.24% year over year. This is 1,526.5 percentage points higher than the US Biotechnology industry revenue growth rate of 145.73%. Seres Therapeutics's revenue in the past year totalled $126.33 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.